全球乙肝治疗市场的价值到2021年缓慢增长至$ 3.5B

StephenW

Global HBV Therapeutics Market Value to Grow Slowly to $3.5B by 2021
Tue, 09/22/2015 - 8:31am
Priyatham Salimadugu, Analyst, GBI Research

Source: Shutterstock
The value of the global Hepatitis B Virus (HBV) therapeutics market will increase modestly over the next 6 years, from almost $3 billion in 2014 to $3.5 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 2.3 percent, said business intelligence provider GBI Research.

The company’s latest report states that this rise will occur across the eight major markets of the US, Canada, the UK, France, Germany, Italy, Spain and Japan, and will be primarily driven by increasing immigration from medium and high-prevalence countries.

The US, which has one of the largest shares of the HBV treatment market, sees considerable migration from high-prevalence countries, such as the Philippines, China, and Vietnam.

While immigration will enlarge the patient pool, HBV treatment market expansion will be restricted by prophylactic vaccination in the US and much of Europe.

However, the increasing use of the premium therapies tenofovir and entecavir will help to drive the market during the forecast period.

Despite this, the global late-stage pipeline is weak due to the lack of first-in-class and innovative products in late-stage clinical development.


The products in late-stage development are either mostly generic, biosimilar or an alternative salt formulation, such as GS-7340, which is a different salt formulation of Viread. As a result, apart from GS-7340, which will capture Viread’s prescription share, the pipeline products are not going to impact the market by 2021.

Furthermore, overall low diagnosis and treatment rates due to the asymptomatic nature of the condition and a lack of awareness, coupled with current drugs serving the market adequately, will hinder further growth. Leading brands treating the condition are also facing competition from generic drugs as major patents approach expiry.”

The patents of HBV therapeutics expected to expire during the forecast period include Roche’s Pegasys, Gilead’s Viread and Novartis’ Sebivo.

StephenW

全球乙肝治疗市场的价值到2021年缓慢增长至$ 3.5B
星期二，2015年9月22日 - 8:31
Priyatham Salimadugu，分析师，GBI研究

资料来源：存在Shutterstock
全球乙肝病毒的价值在2014年（HBV）治疗药物市场将温和增长，在未来6年，从近$ 3十亿至$ 3.5十亿到2021年，占2​​.3％的年复合成长率（CAGR）表示，商业智能供应商GBI研究。

该公司的最新报告指出，这种上涨将出现在美国，加拿大，英国，法国，德国，意大利，西班牙和日本的八大市场，将由来自中，高发病率国家增加移民来主要驱动。

美国，其中有乙肝治疗市场的最大份额之一，看到来自高发病率国家，如菲律宾，中国和越南大量的移民。

虽然移民将扩大病人池，乙肝治疗市场的扩大将通过预防接种，在美国和欧洲大部分地区受到限制。

然而，越来越多地使用保费疗法替诺福韦和恩替卡韦，将有助于在预测期内，带动市场。

尽管如此，全球的后期产品线薄弱由于后期临床开发缺乏第一一流的创新产品。


在后期开发的产品是大多通用的，生物相似或替代盐制剂，如GS-7340，这是Viread的一个不同的盐的制剂。其结果是，除了GS-7340，其将捕获的Viread处方份额，管路的产品不会在2021年冲击市场。

此外，整体低的诊断和治疗率由于病症的无症状性质和缺乏认识，加上目前的药物供应市场充分，会阻碍进一步的增长。领先的品牌治疗病症也面临来自仿制药的竞争，主要的专利接近到期“。

预计在预测期内到期乙肝治疗的专利包括罗氏的派罗欣，Gilead公司的Viread和诺华的替比夫定。